Gurung R, FitzGerald L, Liu E, McComish B, Kaidonis G, Ridge B
BMC Ophthalmol. 2022; 22(1):94.
PMID: 35227220
PMC: 8883612.
DOI: 10.1186/s12886-022-02325-x.
Saw M, Wong V, Ho I, Liew G
Eye (Lond). 2019; 33(12):1842-1851.
PMID: 31227789
PMC: 7002655.
DOI: 10.1038/s41433-019-0494-z.
Gower E, Lovato J, Ambrosius W, Chew E, Danis R, Davis M
Am J Ophthalmol. 2017; 187:138-147.
PMID: 29275147
PMC: 6381823.
DOI: 10.1016/j.ajo.2017.12.007.
Atchison E, Barkmeier A
Curr Ophthalmol Rep. 2017; 4(2):84-89.
PMID: 28580199
PMC: 5432556.
DOI: 10.1007/s40135-016-0098-8.
Kankanala S, Syed R, Gong Q, Ren B, Rao X, Zhong J
Am J Transl Res. 2016; 8(5):2450-8.
PMID: 27347354
PMC: 4891459.
Role of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases.
Zhang S, Gu H, Hu N
J Ophthalmol. 2015; 2015:275435.
PMID: 26146566
PMC: 4471377.
DOI: 10.1155/2015/275435.
Effect of pioglitazone therapy on high sensitive C-reactive protein and lipid profile in diabetic patients with renal transplantation; a randomize clinical trial.
Arashnia R, Roohi-Gilani K, Karimi-Sari H, Nikjoo N, Bahramifar A
J Nephropathol. 2015; 4(2):48-53.
PMID: 25964889
PMC: 4417670.
DOI: 10.12860/jnp.2015.10.
Drug-induced macular edema.
Makri O, Georgalas I, Georgakopoulos C
Drugs. 2013; 73(8):789-802.
PMID: 23640687
DOI: 10.1007/s40265-013-0055-x.
Molecular Implications of the PPARs in the Diabetic Eye.
Ciudin A, Hernandez C, Simo R
PPAR Res. 2013; 2013:686525.
PMID: 23431285
PMC: 3575611.
DOI: 10.1155/2013/686525.
Pioglitazone in the treatment of type 2 diabetes: safety and efficacy review.
Desouza C, Shivaswamy V
Clin Med Insights Endocrinol Diabetes. 2012; 3:43-51.
PMID: 22879786
PMC: 3411525.
DOI: 10.4137/cmed.s5372.
Prescribing of rosiglitazone and pioglitazone following safety signals: analysis of trends in dispensing patterns in the Netherlands from 1998 to 2008.
Ruiter R, Visser L, van Herk-Sukel M, Geelhoed-Duijvestijn P, de Bie S, Straus S
Drug Saf. 2012; 35(6):471-80.
PMID: 22540371
DOI: 10.2165/11596950-000000000-00000.
The use of optical coherence tomography to determine the effect of thiazolidinediones on retinal thickness in patients with type 2 diabetes.
Tarbett A, VanRoekel R, Howard R, Vigersky R
J Diabetes Sci Technol. 2011; 5(4):945-51.
PMID: 21880238
PMC: 3192602.
DOI: 10.1177/193229681100500418.
Diabetic macular edema: correlations with available diabetes therapies--evidence across a qualitative review of published literature from MEDLINE and EMBASE.
Merante D, Menchini F, Truitt K, Bandello F
Drug Saf. 2010; 33(8):643-52.
PMID: 20635822
DOI: 10.2165/11538340-000000000-00000.
Lack of association between thiazolidinediones and macular edema in type 2 diabetes: the ACCORD eye substudy.
Ambrosius W, Danis R, Goff Jr D, Greven C, Gerstein H, Cohen R
Arch Ophthalmol. 2010; 128(3):312-8.
PMID: 20212201
PMC: 3010554.
DOI: 10.1001/archophthalmol.2009.310.
Severe macular edema induced by pioglitazone in a patient with diabetic retinopathy: a case study.
Oshitari T, Asaumi N, Watanabe M, Kumagai K, Mitamura Y
Vasc Health Risk Manag. 2009; 4(5):1137-40.
PMID: 19183764
PMC: 2605323.
DOI: 10.2147/vhrm.s3446.
PPARgamma Agonists: Potential as Therapeutics for Neovascular Retinopathies.
Pershadsingh H, Moore D
PPAR Res. 2008; 2008:164273.
PMID: 18509499
PMC: 2396446.
DOI: 10.1155/2008/164273.
Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus.
Tatti P, Arrigoni F, Longobardi A, Costanza F, Di Blasi P, Merante D
Clin Drug Investig. 2008; 28(5):327-32.
PMID: 18407718
DOI: 10.2165/00044011-200828050-00006.
Thiazolidinediones and their fluid-related adverse effects: facts, fiction and putative management strategies.
Karalliedde J, Buckingham R
Drug Saf. 2007; 30(9):741-53.
PMID: 17722967
DOI: 10.2165/00002018-200730090-00002.
Rosiglitazone for type 2 diabetes mellitus.
Richter B, Bandeira-Echtler E, Bergerhoff K, Clar C, Ebrahim S
Cochrane Database Syst Rev. 2007; (3):CD006063.
PMID: 17636824
PMC: 7389529.
DOI: 10.1002/14651858.CD006063.pub2.
Rosiglitazone (Avandia) and macular edema.
Kendall C, Wooltorton E
CMAJ. 2006; 174(5):623.
PMID: 16467508
PMC: 1389823.
DOI: 10.1503/cmaj.060074.
